American College of Rheumatology (ACR) Convergence | Chicago | 2025 | iPharmaCenter

European Society for Medical Oncology (ESMO) Congress | ESMO 2025 | News | Updates | iPharmaCenter

Lilly’s Oral GLP-1 Orforglipron Shows Superior Results in Two Phase 3 Trials for Type 2 Diabetes | iPharmaCenter

Novo Nordisk Acquires Akero Therapeutics for $4.7 Billion, Expanding Its MASH Portfolio with First-in-Class FGF21 Analogue

FDA Approves Johnson & Johnson’s Simponi (golimumab) as the First Monthly Maintenance Therapy for Pediatric Ulcerative Colitis

Daiichi Sankyo Advances Breast Cancer Portfolio Expansion with ENHERTU approaval in Japan and DATROWAY's positive study

Novartis Ushers in a New Era with FDA Approval of Rhapsido (Remibrutinib) for Chronic Spontaneous Urticaria

AbbVie's Latest Clinical Trial for Alopecia Areata Shows Positive Results | iPharmaCenter

FDA Clears Novo Nordisk’s Wegovy for MASH Treatment | iPharmaCenter

FDA Approves GSK’s Nucala for COPD Patients with Eosinophilic Inflammation

Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter

American College of Cardiology’s (ACC) Annual Scientific Session & Expo | Chicago | News | Updates

Novartis Secures FDA Accelerated Approval for Vanrafia, a Novel Treatment for Proteinuria in IgA Nephropathy

FDA Approves Novartis' Pluvicto for Earlier Treatment of Prostate Cancer | iPharmaCenter

Conference on Retroviruses and Opportunistic Infections (CROI 2025) | San Francisco | iPharmaCenter

AstraZeneca Secures CDSCO Approval for Durvalumab in Limited-Stage Small Cell Lung Cancer Treatment | iPharmaCenter

American Academy of Dermatology (AAD) Annual Meeting | 2025 | News | Updates | iPharmaCenter

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

2025 AAAAI / WAO Joint Congress | American Academy of Allergy, Asthma & Immunology | iPharmaCenter

Sanofi’s Innovative Treatment Rezurock Gains Approval in India for Chronic Graft-Versus-Host Disease (cGVHD) | iPharmaCenter

Winter Clinical Dermatology Conference – Hawaii (WCH) | 2025 | iPharmaCenter

Top Drug Launches to Watch in 2025 | iPharmaCenter

European Hidradenitis Suppurativa Foundation (EHSF) | News | Updates | 2025

FDA Grants Approval for Roche’s Evrysdi Tablet as the First Oral Tablet for Spinal Muscular Atrophy (SMA) | iPharmaCenter

Novartis Strengthens Cardiovascular Portfolio with $3.1 Billion Anthos Therapeutics Acquisition | iPharmaCenter

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2025 in San Francisco | News | Updates | iPharmaCenter

Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter

NICE recommended use of Vertex's £1.6m SCD curative gene therapy, Casgevy | iPharmaCenter

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

Roche’s Itovebi Combination Therapy Shows Significant Survival Benefit in Advanced PIK3CA-mutated, HR-positive, HER2-negative Breast Cancer | iPharmaCenter

Novo Nordisk Completes Promising Phase 1b/2a Study for Amycretin in Overweight and Obesity Treatment

American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium | iPharmaCenter

Sarclisa Receives EU Approval as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Novo Nordisk Unveils Promising Higher-Dose Semaglutide Results for Obesity After CagriSema Setback | iPharmaCenter

AbbVie and Simcere Zaiming Collaborate to Develop Innovative Treatment for Multiple Myeloma | iPharmaCenter

FDA Approves Omvoh for Crohn’s Disease, Expanding Its Reach in Inflammatory Bowel Disease Treatment | iPharmaCenter

Johnson & Johnson Expands Neuroscience Portfolio with Acquisition of Intra-Cellular Therapies | iPharmaCenter

J.P. Morgan Healthcare Conference 2025 | Novartis | Merck | News | Updates

ANVISA Approves Merck's Winrevair for PAH in Brazil | ANVISA Drug Approvals | Aprovações de medicamentos da ANVISA | iPharmaCenter

CVS Launches CostVantage Model; Aims to Bring Transparency at Pharmacies | iPharmaCenter | US Healthcare News

Canada's new healthcare policies are aimed at addressing several healthcare challenges and ensuring equitable access to essential medical services | iPharmaCenter

Amid Failing UK Healthcare System, New NHS Strategy Aims to Cut Waiting Times and Speed Up Patient Care | United Kingdom News | iPharmaCenter

Sanofi Reports Positive Results for Subcutaneous Sarclisa, Aiming to Strengthen Competition with Darzalex | iPharmaCenter

Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter

Valo Health and Novo Nordisk Expand Partnership to Develop Treatments for Cardiometabolic Diseases | iPharmaCenter

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter